Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Breast Neoplasms 134Carcinoma, Non-Small-Cell Lung 133Prostatic Neoplasms 87Lung Neoplasms 43Neoplasms 31Squamous Cell Carcinoma of Head and Neck 30Neoplasm Metastasis 30Stomach Neoplasms 26Head and Neck Neoplasms 24Esophageal Neoplasms 20Parkinson Disease 4, Autosomal Dominant Lewy Body 17Pancreatic Neoplasms 17Ovarian Neoplasms 16Urinary Bladder Neoplasms 13Sarcoma 12Adenocarcinoma of Lung 9Triple Negative Breast Neoplasms 8Fallopian Tube Neoplasms 8Carcinoma, Transitional Cell 8Carcinoma, Ovarian Epithelial 8Adenocarcinoma Of Esophagus 7Recurrence 6Carcinoma 6Inflammatory Breast Neoplasms 5Carcinoma, Squamous Cell 5Breast Neoplasms, Male 5Adenocarcinoma, Bronchiolo-Alveolar 5Adenocarcinoma 5Laryngeal Neoplasms 4Esophageal Squamous Cell Carcinoma 4

Interventions

Gemcitabine 5Cisplatin 4enfortumab vedotin 2Ramucirumab 2Platinum 2Docetaxel 21,2-diaminocyclohexaneplatinum II citrate 2vinflunine 1rucaparib 1pembrolizumab 1eribulin 1enzalutamide 1dehydroftorafur 1carotuximab 1avelumab 1atezolizumab 1Standard of Care 1Specimen Handling 1Radiotherapy 1Radiation 1Paclitaxel 1N-(3-aminopropyl)-N-(1-(5-benzyl-3-methyl-4-oxo-(1,2)thiazolo(5,4-d)pyrimidin-6-yl)-2-methylpropyl)-4-methylbenzamide 1Mitozytrex 1Mitomycin 1Magnetic Resonance Spectroscopy 1Interleukin-7 1Immunoglobulin G 1Icrucumab 1IMC-18F1 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Ureteral Neoplasms × Docetaxel × Clear all
NCT03474107 2026-01-09

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

Astellas Pharma Inc

Phase 3 Completed
608 enrolled 22 charts 1 FDA
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT01282463 2019-09-09

Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma

Eli Lilly and Company

Phase 2 Completed
148 enrolled 19 charts
Genitourinary

Carcinoma, Renal Cell, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡